共 50 条
- [1] FDA Greenlights Second Alzheimer Drug, DonanemabJAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (07):Harris, Emily
- [2] Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer's drugBMJ-BRITISH MEDICAL JOURNAL, 2024, 386Lenzer, JeanneBrownlee, Shannon
- [3] US FDA advisors recommend the approval of obesity drug Qnexa®CLINICAL LIPIDOLOGY, 2012, 7 (02) : 133 - 134Dowdall, Michael
- [4] US FDA defends approval of Alzheimer's disease drugLANCET, 2021, 398 (10294): : 12 - 12Jaffe, Susan
- [5] Ignoring the Experts: Implications of the FDA's Aduhelm ApprovalAMERICAN JOURNAL OF LAW & MEDICINE, 2022, 48 (01) : 108 - 133Maulden, Alexandra
- [6] Alzheimer Drug Lecanemab Gains Traditional FDA ApprovalJAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, : 495Harris, Emily
- [7] FDA calls for investigation into industry influence during Alzheimer's drug approvalBMJ-BRITISH MEDICAL JOURNAL, 2020, 374 : n1778Dyer, Owen
- [8] FDA advisers recommend approval of biosimilar filgrastimAMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (04) : 262 - +Traynor, Kate
- [9] Three FDA advisory panel members resign over approval of Alzheimer's drugBMJ-BRITISH MEDICAL JOURNAL, 2021, 373 : n1503Mahase, Elisabeth
- [10] FDA and drug approvalJOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 1995, 6 (06) : S24 - S24Faich, GA